ReviewPLoS pathogens2026
The Nipah virus threat in India: Epidemiological trends, risk drivers, and lessons for pandemic preparedness.
Review in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nipah virus (NiV), a WHO-priority zoonotic pathogen, poses a recurrent public health threat in India. Since its initial detection in 2001, India has encountered multiple NiV spillover events, including repeated outbreaks in Kerala and recent cases reported in West Bengal in 2026. Although the pig-amplified epidemic in Malaysia (1998-1999) and the seasonal outbreaks associated with NiV-contaminated date palm sap consumption in Bangladesh are extensively documented, India represents a unique and relatively understudied epidemiological setting. NiV outbreaks in India are primarily linked to the NiV-Bangladesh clade and are marked by direct spillover transmission from bats to humans, elevated case-fatality rates, clustered emergence, and effective household/nosocomial transmission without an intermediate amplifying host. Spillover risk is influenced by region-specific ecological and socio-economic factors, including contamination of peri-domestic fruit, proximity of bat roosts to human settlements, deforestation, and urban expansion. To date, no treatment or vaccine is available for humans or animals. This review synthesizes evidence from India spanning 2001 to 2026. It integrates aspects of epidemiology, bat reservoir ecology, viral genomics, clinical manifestations, surveillance experiences, and health system responses, while contrasting India's transmission dynamics with those observed in Malaysia and Bangladesh. Furthermore, we explore India's current preparedness and response strategies, highlighting the critical shift from reactive outbreak control to a proactive, integrated "One Health" framework. The strategy to strengthen integrated surveillance, contact tracing, isolation, and quarantine of suspected and confirmed cases, advance India-developed vaccines and therapeutics, and address the root ecological drivers of zoonotic emergence is essential for national and global health security.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.